Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
- Registration Number
- NCT01719380
- Lead Sponsor
- Pfizer
- Brief Summary
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 156
- Metastatic colorectal cancer
- Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
- Life expectancy ≥ 3 months
- ECOG performance status ≤ 2
- Symptomatic or untreated leptomeningeal disease
- Symptomatic brain metastasis
- Patients with clinically manifested diabetes
- Acute or chronic pancreatitis
- Clinically significant cardiac disease
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LGX818 + cetuximab LGX818 - LGX818 + cetuximab Cetuximab - LGX818 + BYL719 + cetuximab BYL719 - LGX818 + BYL719 + cetuximab LGX818 - LGX818 + BYL719 + cetuximab Cetuximab -
- Primary Outcome Measures
Name Time Method Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1 Cycle 1: Day 1 to Day 28 DLTs were defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first 28 days of treatment and meets any of the criteria included blood and lymphatic system disorders, investigations (blood, renal, hepatic, metabolic), skin and subcutaneous tissue disorders: rash, HFSR (hand foot skin reaction) and/or photosensitivity, metabolism and nutrition disorders: hyperglycemia, gastrointestinal disorders, cardiac disorders, vascular disorders, general disorders and administration site conditions, tumor lysis syndrome, ophthalmologic and other adverse events: study drug-related fever, alkaline phosphatase elevation.
Phase 2: Progression Free Survival (PFS) From the date of randomization until the first documentation of disease progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months) PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. Participants who did not progress per RECIST (Response Evaluation Criteria in Solid Tumors) version (v) 1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
- Secondary Outcome Measures
Name Time Method Apparent Total Plasma Clearance at Steady State (CL/F, ss) of BYL719 (Alpelisib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Tmax was defined as the time to reach maximum observed plasma concentration of encorafenib.
Apparent Total Plasma Clearance at Steady State (CL/F, ss) of LGX818 (Encorafenib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0 From screening up to 30 days after the last dose of study treatment (for a maximum duration of 43 months, approximately) An AE was any untoward medical occurrence attributed to study drug in participants who received study drug. As per NCI-CTCAE v4.0, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to study drug. Treatment-emergent AEs are between first dose of study drug and up to 30 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. Number of participants with any Grade 3 or 4 treatment-emergent AE were reported in this outcome measure.
Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of LGX818 (Encorafenib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Volume of distribution at steady state is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of LGX818 (Encorafenib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Tmax, ss was defined as the time to reach maximum observed plasma concentration of LGX818 (encorafenib) at steady state.
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of BYL719 (Alpelisib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Tmax was defined as the time to reach maximum observed plasma concentration of alpelisib.
Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose T-last was defined as the time to reach last observed plasma concentration of alpelisib.
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of BYL719 (Alpelisib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Tmax, ss was defined as the time to reach maximum observed plasma concentration of BYL719 (alpelisib) at steady state.
Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib) Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose T-last was defined as the time to reach last observed plasma concentration of encorafenib.
Duration of Response (DOR) From the first documentation of OR (confirmed CR or PR) to first documentation of PD/death due to any cause or censoring date, whichever occurred first (up to 43 months) DOR: Time between date of the first documented response (CR or PR) and the date of first documented PD or death due to underlying cancer. If PD or death due to underlying cancer not occurred, then participant was censored at the date of last tumor assessment other than unknown. DOR was calculated for responders (confirmed) only. CR: Disappearance of all target, non-target lesions sustained for \>=4 weeks and any pathological lymph nodes reduced in short axis to \<10mm. PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameter. PD for target lesions: At least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study treatment, with absolute increase of \>=5 mm, or appearance of \>=1 new lesions. PD for non-target lesions: Unequivocal progression of pre-existing lesions/increase in overall tumor burden leading to discontinuation of therapy or appearance of new unequivocal malignant lesion.
Time to Response (TTR) From the date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first (maximum up to 43 months) TTR as assessed by investigator according to RECIST v1.1, was defined as the time (in months) from date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) reduced in short axis to \<10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not achieve a confirmed PR or CR, were censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease) or at maximum follow-up (from study start to study end date) when participant had an event for progression-free survival.
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of LGX818 (Encorafenib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose T-last, ss was defined as the time to reach last observed plasma concentration of encorafenib at steady state.
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of BYL719 (Alpelisib) Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose T-last, ss was defined as the time to reach last observed plasma concentration of alpelisib at steady state.
Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib) Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Ctrough, ss was defined as plasma trough concentration of encorafenib at steady state.
Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib) Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose Ctrough, ss was defined as plasma trough concentration of alpelisib at steady state.
Overall Survival (OS) From the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first (up to 43 months) OS was defined as the time (in months) from the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Phase 1b: Progression Free Survival (PFS) From date of start of treatment to the date of event defined as the first documented progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months) PFS was defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. Participants who did not progress per RECIST v1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
Phase 2: Number of Participants With Any Variant in Gene Status at Baseline Baseline (Day 1) Gene alterations/expression relevant to the RAF/MEK/ERK (proto-oncogene serine/threonine-protein kinase/ mitogen-activated ERK kinase/ extracellular signal-regulated kinases) and EGFR/PI3K/AKT (epidermal growth factor receptor/ phosphatidylinositol 3-kinase/ protein kinase B) pathways in tumor tissue, baseline molecular status (mutation/amplification/expression) in tumor tissue of potential predictive markers of tumor response or resistance i.e. BRAF (v-raf murine sarcoma viral oncogene homolog B1), HRAS (harvey rat sarcoma protein), KRAS (V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog B1), NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), PIK3CA (phosphatidylinositol 3-kinase gene), MAP2K1 (mitogen-activated protein kinase 1), MAP2K2 (mitogen-activated protein kinase 2), ARAF, c-MET, RAF1, EGFR was analyzed.
Overall Response Rate (ORR) From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause (maximum up to 43 months) Overall response rate as assessed by the investigator per RECIST v1.1, was defined as percentage of participants with a best overall response of complete response (CR) or partial response (PR), were recorded from date of randomization or date of start of treatment until date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target and non-nodal target lesions, and sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Only confirmed CR and PR are counted (those confirmed at least 4 weeks).
Trial Locations
- Locations (41)
UCLA Santa Monica Medical Center & Orthopaedic Hospital
🇺🇸Santa Monica, California, United States
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Erasmus MC
🇳🇱Rotterdam, Zuid-holland, Netherlands
Royal Melbourne Hospital
🇦🇺Parkville, Victoria, Australia
Yale University
🇺🇸New Haven, Connecticut, United States
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
🇳🇱Amsterdam, Noord-holland, Netherlands
UZ Gasthuisberg
🇧🇪Leuven, Vlaams Brabant, Belgium
Pharmacy of National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
LAC&USC Medical Center
🇺🇸Los Angeles, California, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Keck Hospital of USC
🇺🇸Los Angeles, California, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Smilow Cancer Hospital Care Center at North Haven
🇺🇸North Haven, Connecticut, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Westwood Bowyer Clinic, Peter Morton Medical Building
🇺🇸Los Angeles, California, United States
UCLA University of California Los Angeles
🇺🇸Los Angeles, California, United States
UCLA Hematology Oncology
🇺🇸Santa Monica, California, United States
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Huntsman Cancer Hospital
🇺🇸Salt Lake City, Utah, United States
Universitätsklinikum Essen
🇩🇪Essen, Germany
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
John A Moran Eye Center
🇺🇸Salt Lake City, Utah, United States
Smilow Cancer Hospital at Yale-New Haven
🇺🇸New Haven, Connecticut, United States
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
🇫🇷Montpellier, France
University Hospital of Koln
🇩🇪Köln, Nordrhein-westfalen, Germany
Tennessee Oncology, PLLC
🇺🇸Smyrna, Tennessee, United States
University of Utah - Huntsman Cancer Institute - PPDS
🇺🇸Salt Lake City, Utah, United States
Redwood Health Center - ARUP Lab Draw Location
🇺🇸Salt Lake City, Utah, United States
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
🇪🇸Barcelona, Spain
EDOG - Institut Claudius Regaud - PPDS
🇫🇷Toulouse, France
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
Asan Medical Center - PPDS
🇰🇷Songpa-Gu, Seoul Teugbyeolsi, Korea, Republic of
Oslo Myeloma Center - PPDS
🇳🇴Oslo, Norway
Hospital Universitario Virgen del Rocio - PPDS
🇪🇸Sevilla, Spain
Ospedaliero Universitaria di Modena Policlinico
🇮🇹Modena, Italy
Sir Mortimer B. Davis Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Samsung Medical Center - PPDS
🇰🇷Gangnam-Gu, Seoul Teugbyeolsi, Korea, Republic of